<DOC>
	<DOC>NCT00630357</DOC>
	<brief_summary>A cohort of patients who became seizure-free during add-on treatment to one standard AED with Keppra in a previous trial (N01031) were followed to assess whether seizure freedom was maintained. Tolerability was documented.</brief_summary>
	<brief_title>Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Diagnosis of epilepsy with partial seizures; having completed the trial N01031 of Keppra as adjunctive therapy (SKATE); seizurefree over the last 3 months prior to protocol Visit 1; 1 concomitant marketed AED at the time of trial entry and throughout the previous trial N01031; on the clinical judgment of the Investigator, progressive withdrawal of the concomitant AED and conversion to monotherapy with Keppra can be attempted. History of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous 5 years; presence of known pseudoseizures within the last year; presence or history of allergy to the components of Keppra (levetiracetam, lactose, cornstarch, and excipients) or other pyrrolidine derivatives; felbamate with less than 18 months exposure; vigabatrin, without visual field assessment as per recommendation of the manufacturer, i.e., every 6 months; uncountable seizures (clusters) or history of convulsive status epilepticus within the last 5 years.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>